Cited 8 times in
Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 차봉수 | - |
dc.date.accessioned | 2022-09-02T01:07:42Z | - |
dc.date.available | 2022-09-02T01:07:42Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/189974 | - |
dc.description.abstract | We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were -0.79% and -0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, -0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (-11.9% vs. -4.8%;P < .0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | DIABETES OBESITY & METABOLISM | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Blood Glucose | - |
dc.subject.MESH | Diabetes Mellitus, Type 2* / drug therapy | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Glycated Hemoglobin A / analysis | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents / adverse effects | - |
dc.subject.MESH | Metabolic Syndrome* | - |
dc.subject.MESH | Metformin* / adverse effects | - |
dc.subject.MESH | Pyrimidines | - |
dc.subject.MESH | Sitagliptin Phosphate / adverse effects | - |
dc.subject.MESH | Thiazolidinediones | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sin Gon Kim | - |
dc.contributor.googleauthor | Kyoung Jin Kim | - |
dc.contributor.googleauthor | Kun Ho Yoon | - |
dc.contributor.googleauthor | Sung Wan Chun | - |
dc.contributor.googleauthor | Kyong Soo Park | - |
dc.contributor.googleauthor | Kyung Mook Choi | - |
dc.contributor.googleauthor | Soo Lim | - |
dc.contributor.googleauthor | Ji-Oh Mok | - |
dc.contributor.googleauthor | Hyoung Woo Lee | - |
dc.contributor.googleauthor | Ji A Seo | - |
dc.contributor.googleauthor | Bong-Soo Cha | - |
dc.contributor.googleauthor | Mi Kyung Kim | - |
dc.contributor.googleauthor | Ho Sang Shon | - |
dc.contributor.googleauthor | Dong Seop Choi | - |
dc.contributor.googleauthor | Doo Man Kim | - |
dc.identifier.doi | 10.1111/dom.14085 | - |
dc.contributor.localId | A03996 | - |
dc.relation.journalcode | J00722 | - |
dc.identifier.eissn | 1463-1326 | - |
dc.identifier.pmid | 32406573 | - |
dc.identifier.url | https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14085 | - |
dc.subject.keyword | clinical trial | - |
dc.subject.keyword | lobeglitazone | - |
dc.subject.keyword | randomized trial | - |
dc.subject.keyword | thiazolidinediones | - |
dc.subject.keyword | type 2 diabetes | - |
dc.contributor.alternativeName | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | 차봉수 | - |
dc.citation.volume | 22 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1869 | - |
dc.citation.endPage | 1873 | - |
dc.identifier.bibliographicCitation | DIABETES OBESITY & METABOLISM, Vol.22(10) : 1869-1873, 2020-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.